|
Vaccine Detail
rLAG- PA-DCpep |
Vaccine Information |
- Vaccine Name: rLAG- PA-DCpep
- Target Pathogen: Bacillus anthracis
- Target Disease: Anthrax
- Vaccine Ontology ID: VO_0004715
- Type: Recombinant vector vaccine
- Status: Research
- Host Species for Licensed Use: Mouse
- pagA
gene engineering:
- Type: Recombinant vector construction
- Description:
- Detailed Gene Information: Click Here.
- Vector:
- Preparation: Targeted B. anthracis protective antigen (PA) genetically fused to a DC-binding peptide (DCpep) was delivered by Lactobacillus acidophilus (Mohamadzadeh et al., 2010)
- Immunization Route: Intramuscular injection (i.m.)
|
Host Response |
Mouse Response
- Vaccination Protocol: Groups of mice were orally vaccinated with 100 µl (108 CFU) L. gasseri expressing PA–DCpep, PA–Ctrlpep, or cells harboring the empty vector. Oral vaccination was administered four times on a weekly basis (Mohamadzadeh et al., 2010).
- Vaccine Immune Response Type: VO_0003057
- Challenge Protocol: The groups of mice were challenged intraperitoneally with B. anthracis Sterne pXO1+/pXO2- (5 × 10^4 CFU/mouse) (Mohamadzadeh et al., 2010).
- Efficacy: L. gasseri expressing PA–DCpep fusion was 100% efficacious in protection of the mice compared with 30% survival when vaccinated with L. gasseri expressing PA–Ctrl pep (Figure 3A & B). Additionally, vaccinated mice with recombinant PA plus alhydrogel were fully protected from Sterne lethal challenge (Mohamadzadeh et al., 2010).
|
References |
Mohamadzadeh et al., 2010: Mohamadzadeh M, Durmaz E, Zadeh M, Pakanati KC, Gramarossa M, Cohran V, Klaenhammer TR. Targeted expression of anthrax protective antigen by Lactobacillus gasseri as an anthrax vaccine. Future microbiology. 2010; 5(8); 1289-1296. [PubMed: 20722604].
|
|